Project Grant R43HL149499

This $651,840 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a novel kidney health monitoring system, called the Kidney Tubule Health Panel (KTHP), to improve treatment of resistant hypertension. The goal is to use KTHP biomarkers to differentiate benign creatinine changes from acute kidney injury during hypertension treatment, addressing a critical unmet need. The 4-year project...

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded Antlia Bioscience, Inc. a Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) totaling $999,998.00 to develop a novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), for the treatment of resistant hypertension. The funding will support bulk manufacturing of the clinical-grade PAS(400)-hBNP compound, pharmacokinetic and...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $999,615 to Extend Biosciences Inc. to develop a long-acting parathyroid hormone (PTH) derivative, EXT608, for the treatment of hypoparathyroidism. The key product under this award is the advancement of EXT608 through clinical trials, including a Phase 2 study to evaluate the...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $386,592 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Pennsylvania State University to develop a soft, stretchable, and bioadhesive electronic device for minimally invasive neuromodulation therapy to treat resistant hypertension. The key objectives are to: 1) develop 3D-printable stretchable bioadhesive materials to enable stable long-term device-tissue interfacing; 2) optimize the soft,...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Covenant Therapeutics LLC a $249,965 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) on September 10, 2023. The purpose of this grant is to further develop a novel therapeutic approach involving small peptide erythropoietin (EPO) analogs as an alternative to recombinant human EPO for the treatment of anemias, particularly those secondary to renal disease and malignancy. The key objectives are to optimize the lead...

This federal Project Grant award of $262,808 from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) supports research led by Beth Israel Deaconess Medical Center, Inc. (Bidmc) to develop water-soluble prodrugs of the novel compound AKT-1005 for treating preeclampsia, a life-threatening pregnancy complication. The research aims to improve the solubility, stability, and pharmacokinetic properties of AKT-1005, which...

This Project Grant award in the amount of $1,325,500 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel PAC1 receptor antagonists for the treatment of medication overuse headache (MOH). The primary objective is to identify and characterize promising lead PAC1 receptor antagonist compounds that could serve as targeted therapies for MOH, which can develop as a result of...

The federal Project Grant award of $747,911 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund the implementation and evaluation of the RI-SPHERES program. RI-SPHERES is a technology-based collaborative care model that aims to reduce short- and long-term morbidity associated with hypertensive disorders of pregnancy (HDP) in Rhode Island. The key products and services to be...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $333,000 to the University of Connecticut Health Center to conduct a randomized, double-blind, controlled pilot study on the efficacy and safety of levothyroxine (LT4) and liothyronine (LT3) combination therapy for the treatment of hypothyroidism. The study aims to evaluate whether a...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will support research and development of an innovative "Diabetes Targeted Dual Neuromodulation Therapy" (TDN Therapy) by Reshape Lifesciences Inc., a small business joint venture. The $345,650 award will fund a Phase I feasibility study to validate the hypothesis that decreased TDN therapy...